Pacific Heights Asset Management LLC Raises Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Pacific Heights Asset Management LLC boosted its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 52.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 700,000 shares of the company’s stock after buying an additional 240,000 shares during the period. Pacific Heights Asset Management LLC’s holdings in Structure Therapeutics were worth $19,600,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in GPCR. State of Wyoming purchased a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $28,000. Assetmark Inc. raised its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after purchasing an additional 820 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Structure Therapeutics by 29.1% during the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Structure Therapeutics during the second quarter valued at approximately $129,000. Finally, Signaturefd LLC grew its stake in Structure Therapeutics by 6,550.0% in the 2nd quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock worth $138,000 after buying an additional 6,550 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Trading Up 4.3%

Shares of NASDAQ:GPCR opened at $88.64 on Tuesday. The stock has a market capitalization of $5.38 billion, a P/E ratio of -72.66 and a beta of -2.05. The stock’s 50-day moving average price is $56.40 and its 200-day moving average price is $34.72. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $13.22 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several research reports. Stifel Nicolaus raised their price objective on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Morgan Stanley lifted their price target on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Citizens Jmp increased their price objective on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research report on Friday, December 12th. Finally, Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $99.40.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.